Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.26

+1.2%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doc Bones who wrote (13433)	10/11/2004 9:47:48 AM
From: Biomaven	Read Replies (2) of 52153

Interesting presentation on the future of cancer clinical trials by Daniel von Hoff at the Arqule analyst day: corporate-ir.net His presentation is the first 25 minutes or so. He says the FDA is potentially moving to a new scheme for targeted drugs where the company has to show 25 responses out of 275 patients in order to get approval. So if you can figure out which patients your drug works in, you can get approval with small trials. He also has some interesting things to say about Phase I and II trials. He says 4 months stable disease is a key response to aim for, and there should be less focus on PR's and CR's and more focus on quality of life issues for the patients. He argues for bigger Phase II's (75 patients) so you don't get failed Phase III's. Well worth listening to. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next